Efficacy and Safety of Low‐Frequency Daratumumab Regimen in Systemic Light‐Chain Amyloidosis

ABSTRACT In recent years, daratumumab has been increasingly applied in the treatment of systemic light‐chain (AL) amyloidosis, significantly improving the prognosis of patients. Currently, the internationally recognized daratumumab treatment regimen comes from the ANDROMEDA trial. Given the low tumo...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jintao Lin, Hui Yan, Xinyi Meng, Jingsong He, Jinuo Wang, Xiaoyan Han, Jian Shen, Qiu Fang, Li Huang, Gaofeng Zheng, Wenjun Wu, Yi Zhao, Yi Li, Li Yang, Xing Guo, Jing Chen, Haimeng Yan, Zhen Cai, Donghua He
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2026-07-01
Edice:	Cancer Medicine
Témata:	AL amyloidosis CD38 daratumumab Low‐frequency therapy plasma‐cell
On-line přístup:	https://doi.org/10.1002/cam4.72103
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!